Physician profile
Andre G Serrette
NPI 1558522888
$11,897.32
in general payments reported to CMS, 2019-2025
43 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 96% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $1,763 · 2021: $2,682 · 2022: $1,459 · 2023: $1,126 · 2024: $1,685 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,720.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,261.42 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,008.94 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $946.18 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $913.77 | 2021-2024 | Ubrelvy, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $821.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $698.25 | 2019-2022 | |
| Lilly USA, LLC | $620.93 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $577.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $562.66 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $469.51 | 2019-2023 | Xarelto |
| Allergan, INC. | $456.75 | 2019-2020 | |
| Eisai INC. | $394.89 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $381.07 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $329.84 | 2022-2025 | Caplyta |
| Abbott Laboratories | $219.85 | 2021-2024 | Freestyle Libre 3 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $208.27 | 2019-2023 | |
| Redhill Biopharma INC. | $201.76 | 2020-2022 | |
| Axsome Therapeutics, INC. | $173.83 | 2025 | Symbravo, Auvelity |
| Sunovion Pharmaceuticals INC. | $166.09 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $164.42 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $147.21 | 2022 | |
| Amgen INC. | $143.09 | 2020-2025 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $131.78 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Exact Sciences Corporation | $110.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Acadia Pharmaceuticals INC | $73.06 | 2020-2021 | |
| Mylan Specialty L.P. | $69.70 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $55.48 | 2019-2020 | |
| Alk-Abello, INC | $54.47 | 2024 | Grastek, Ragwitek, Odactra |
| Shield Therapeutics INC | $52.50 | 2025 | |
| Jazz Pharmaceuticals INC. | $50.71 | 2021 | |
| Esperion Therapeutics, INC. | $49.28 | 2021-2022 | |
| Optinose US, INC. | $44.98 | 2023-2024 | |
| Corcept Therapeutics | $44.01 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $43.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $43.12 | 2023 | Quviviq |
| Genentech USA, INC. | $36.10 | 2019-2022 | |
| Dexcom, INC. | $33.35 | 2025 | Dexcom G6 Transmitter |
| Medicomp INC | $26.95 | 2025 | Telepatch Cardiac Monitor |
| Takeda Pharmaceuticals U.S.A., INC. | $25.77 | 2024 | Trintellix |
| Dermira, INC. | $25.48 | 2019 | |
| Phadia US INC. | $23.42 | 2025 | Immunocap |
| Lundbeck LLC | $20.70 | 2019 | |
| Shionogi INC | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Serrette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.